IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
RMDL: Classification of Parkinson's disease by nature-inspired Algorithm
Antidiabetic activity (In vitro alpha amylase inhibitory) of ethanol extract of Carissa carandas Linn. roots.
Six sigma: an embellished exploration in the field of pharmaceutical industry
The effect of Sida acuta on bacterial enzymes in azoxymethane-induced experimental colon cancer
Premature ageing in children: a rare genetic disorder called progeria.
Stress, Depression & Gut Microbiota: The Gut-Brain Axis Regulation
Zinc oxide nanoparticles and antibiotics mediated combinatorial approach to enhance antibacterial potential
Quality of life and associated factors among students in Jambi Province, Indonesia
Novel method for simultaneous determination of spiramycin and metronidazole in pharmaceutical dosage form by UV-visible absorption spectrophotometry
The Influence of Physicians Social Capital on Patients Satisfaction
1234
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Bio-Analytical Method Development and Validation For The Concurrent Quantification of Hydrochlorothiazide And Valsartan By Using Losartan As Internal Standard In Human Plasma By LC-MS/MS

Author: JITHIN JOHN, NAGARAJAN JANAKI SANKARACHARI KRISHNAN, KRISHNAVENI R, TAMADRI DAS, ANN RAICHEL JOHN
Abstract: A simple, rapid, specific and sensitive method has been proposed for the development and validation of bio-analytical method for the concurrent quantification of hydrochlorothiazide and valsartan using losartan as an internal standard in human blood plasma by LC-MS/MS. The separation was achieved using ZORBAX SB C18 (5µmx50x3.6mm i.d.), mobile phase containing Cyanomethane: Ammonium Formate (70:30v/v) pH adjusted to 4.25 and flow rate of the mobile phase was 0.5ml/min and the injection volume 10µl and the column oven temperature is ambient. The retention time of hydrochlorothiazide (HCT) and valsartan (VST) was found to be 1.22 and 1.08min, respectively. The developed method was found to be linear over the concentration range of 420-8400 (r2 value 0.9932) and 6-122ng/ml (r2 value 0-9954) using losartan as internal standard. LOD and LOQ of valsartan 1 and 3ng/ml and that of hydrochlorothiazide was 0.5 and 2 ng/ml respectively. Shimadzu LC-MS/MS 8030 was configured with Lab solution data solution, Triple quadrupole analyzer, ESI interface. Hydrochlorothiazide and valsartan were extracted by Liquid-Liquid extraction method. According to USFDA guidelines the method was established and validated. This method can applicable for the Pharmacokinetic, Bioequivalence and Bioavailability studies contains valsartan and hydrochlorothiazide.
Keyword: Bio-analytical, Human Plasma, Valsartan, Hydrochlorothiazide, LC-MS/MS.
DOI: https://doi.org/10.31838/ijpr/2020.12.02.0007
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free